[{"id":"18f962e9-1e81-4662-aefa-d45609626eba","acronym":"IMscin002","url":"https://clinicaltrials.gov/study/NCT05171777","created_at":"2021-12-29T14:53:52.120Z","updated_at":"2024-07-02T16:35:00.373Z","phase":"Phase 2","brief_title":"A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05171777 - IMscin002","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 04/04/2022","start_date":" 04/04/2022","primary_txt":" Primary completion: 11/09/2023","primary_completion_date":" 11/09/2023","study_txt":" Completion: 09/20/2024","study_completion_date":" 09/20/2024","last_update_posted":"2024-05-29"},{"id":"4dc5ef96-57fd-4afb-9410-77e05a570d25","acronym":"IMscin001","url":"https://clinicaltrials.gov/study/NCT03735121","created_at":"2021-01-18T18:17:44.227Z","updated_at":"2024-07-02T16:35:12.987Z","phase":"Phase 3","brief_title":"A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03735121 - IMscin001","lead_sponsor":"Hoffmann-La Roche","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 438","initiation":"Initiation: 12/14/2018","start_date":" 12/14/2018","primary_txt":" Primary completion: 04/26/2022","primary_completion_date":" 04/26/2022","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-25"},{"id":"3ffca675-0273-4289-8d96-fecb734298cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05340309","created_at":"2022-04-22T14:53:46.319Z","updated_at":"2024-07-02T16:35:19.527Z","phase":"Phase 2","brief_title":"Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05340309","lead_sponsor":"University of Southern California","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/07/2022","start_date":" 12/07/2022","primary_txt":" Primary completion: 12/07/2025","primary_completion_date":" 12/07/2025","study_txt":" Completion: 12/07/2026","study_completion_date":" 12/07/2026","last_update_posted":"2024-02-13"},{"id":"e5a8e0c7-3d27-4fa1-bebf-518326e168c8","acronym":"CMP-001-003","url":"https://clinicaltrials.gov/study/NCT03438318","created_at":"2021-01-18T16:56:58.252Z","updated_at":"2024-07-02T16:36:06.118Z","phase":"Phase 1b","brief_title":"Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03438318 - CMP-001-003","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • vidutolimod (CMP-001) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/15/2018","start_date":" 03/15/2018","primary_txt":" Primary completion: 12/11/2019","primary_completion_date":" 12/11/2019","study_txt":" Completion: 12/11/2019","study_completion_date":" 12/11/2019","last_update_posted":"2022-08-03"}]